paliroden
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2003 (NCT00228150)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Beta-nerve growth factorACTIVATOR
NGF activator
Chemistry & pharmacology
Loading structure…
SMILES
FC(F)(F)c1cccc(C2=CCN(CCc3ccc(-c4ccccc4)cc3)CC2)c1- Mol. weight
- 407.48 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2107767 ↗
Also known as
- paliroden
- sr57667b
- sr57667b
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00285025 | Phase 2 | Mar 1, 2005 | Sanofi |
| NCT00285077 | Phase 2 | Mar 1, 2004 | Sanofi |
| NCT00220272 | Phase 2 | Jan 1, 2004 | Sanofi |
| NCT00228150 | Phase 2 | Jul 1, 2003 | Sanofi |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 4 | 4 | 1 | 2003 |
1 organizations
Page 1 / 1